Loading page content…
Loading page content…
| Source: | Find a Tender Service (FTS) |
| Buyer: | MEDICINES DISCOVERY CATAPULT LIMITED |
| Main Category: | Goods |
| Procurement Method: | Direct award |
| Tender Status: | Complete |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 22 September 2025 |
| Application Deadline: | — |
| Procurement ID (OCID): | ocds-h6vhtk-059ecc |
| Notice Reference: | 058392-2025 |
View Original Notice
Access the full notice on the official portal
MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications. These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow. SPECT imaging enables biodistribution studies for isotopes that PET cannot support. This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scientific and clinical needs. We have a clear opportunity to address this gap by introducing SPECT and CT capability through the phased procurement of the SPECT Cube module, followed by an upgrade to the advanced SPECT Cube 2.0 platform. This will allow MDC to meet rising diagnostic demand, align with industry standards, and maintain clinical competitiveness.
Published contracts in the last 12 months
39
total contracts
£5.8m
total value
£524,999
average contract size
Typical categories
Pipeline status
Not addedContract imported automatically · AI writes the response
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →